gdc

ASH 2019 CLL

ASH 2019 CLL
Targeted drug treatments for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) are given indefinitely: either until disease progression or until side effects are no longer manageable. A key question is whether oncologists can use results of minimal residual disease (MRD) testing to determine if patients can take a break from treatment with targeted drugs.
ASH 2019 CLL
Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that is particularly difficult to treat if the patient becomes refractory to or relapses after initial treatment. Chances of survival are especially poor for people who are not eligible for stem-cell transplant.
ASH 2019 CLL
Mantle-cell lymphoma is a relatively aggressive type of non-Hodgkin lymphoma. Results from a study of patients who elected to interrupt treatment with ibrutinib plus venetoclax are presented.
ASH 2019 CLL
A study evaluating the safety and efficacy of a new 3-drug combination is underway in patients with relapsed and refractory chronic lymphocytic leukemia (CLL).
ASH 2019 CLL
Zanubrutinib is an investigational, next-generation Bruton tyrosine kinase inhibitor. It has been tested in previously untreated patients with del(17p) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who are enrolled in the SEQUOIA trial.
ASH 2019 CLL
Zanubrutinib is a next-generation Bruton tyrosine kinase inhibitor that has been shown to be potent and selective. Preliminary data suggest durable clinical responses in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
ASH 2019 CLL
Updated analysis of ASCEND trial showed that acalabrutinib, a highly selective Bruton tyrosine kinase inhibitor, improves progression-free survival compared with other treatments for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
ASH 2019 CLL
Results from a study of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to see if treatment with ibrutinib plus venetoclax could be stopped for those who have a good response.
ASH 2019 CLL
An updated analysis of combined or pooled data from studies of ibrutinib. For the first time, a comparison of outcomes with ibrutinib versus patients’ prior treatment regimens for mantle-cell lymphoma is shared.
ASH 2019 CLL
In a study that compared VenR (venetoclax plus rituximab) with standard chemoimmunotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), initial reports showed superior progression-free survival for VenR, as well as long-term benefits after patients stopped therapy.
Page 1 of 2
Results 1 - 10 of 15

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country